The response of a patient with Langerhans Cell Histiocytosis (LCH) to therapy can be classified into semi-quantitative categories (LCH III).
Patient selection: Langerhans Cell Histiocytosis ay 6 weeks after therapy
Mixed: regression in one site AND progression in another
Stable: neither regression nor progression
Worse: progression of signs and symptoms and/or appearance of new lesions
Signs and Symptoms
To read more or access our algorithms and calculators, please log in or register.
Specialty: Hematology Oncology